Physician profile
Mohammad M Yaqub
NPI 1164616157
$1,925.08
in general payments reported to CMS, 2019-2025
23 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.42 · 2022: $182 · 2023: $429 · 2024: $796 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.00 | 2022-2025 | Qulipta, Ubrelvy |
| Abbott Laboratories | $282.71 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Shield Therapeutics INC | $238.38 | 2023-2024 | Accrufer |
| Novo Nordisk INC | $165.23 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $130.74 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $118.32 | 2024-2025 | Rexulti, Jynarque |
| Lilly USA, LLC | $108.29 | 2022-2025 | Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $91.36 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $75.78 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.76 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $57.33 | 2023-2024 | Shingrix, Arexvy |
| Lundbeck LLC | $53.51 | 2024-2025 | Rexulti |
| Calliditas Therapeutics US INC. | $28.45 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.90 | 2024 | Givlaari |
| Astellas Pharma US INC | $24.72 | 2025 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $24.20 | 2023 | Seglentis |
| Dexcom, INC. | $24.08 | 2024 | Dexcom G6 Transmitter |
| Abiomed | $23.54 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2022 | |
| Esperion Therapeutics, INC. | $16.42 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.21 | 2024 | Farxiga |
| Exact Sciences Corporation | $14.32 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Yaqub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.